Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
复制标题
DOI：
10.1111/j.1365-2141.2012.09241.x
复制
发表时间：
2012-09-01
影响因子：
6.5
通讯作者：
Berenson, James R.
中科院分区：
文献类型：
--
作者：
Sanchez, Eric;Li, Mingjie;Berenson, James R.
虽然TNFRSF17（也称为B细胞成熟抗原（BCMA））在B细胞恶性肿瘤的肿瘤细胞上表达，但在血清中未发现。本研究发现，BCMA浓度高于培养的骨髓单个核细胞的上清液中的多发性骨髓瘤（MM）患者比健康受试者。在来自MM患者（n = 209）、意义不明的单克隆丙种球蛋白病（MGUS）个体（n = 23）和年龄匹配的对照（n = 40）的样品中测量血清BCMA水平。MM患者血清BCMA水平明显高于MGUS患者（P = 0.0157）和健康人（P <0.0001）。疾病进展患者（n = 80）的血清BCMA水平高于疾病缓解患者（n = 79; P = 0.0038）。在所有MM患者中，血清BCMA水平高于中位数的患者的总生存期较短（P = 0.001）。我们还证明了来自人MM异种移植物小鼠的血清含有人BCMA，并且水平与对美法仑或环磷酰胺与硼替佐米的反应中肿瘤体积的变化相关。这些结果表明，血清BCMA水平可能是监测MM患者疾病状态和总生存期的新生物标志物。
Although TNFRSF17 (also designated as B-cell maturation antigen (BCMA)) is expressed on tumour cells in B-cell malignancies, it has not been found in serum. The present study found that BCMA concentrations were higher in the supernatants of cultured bone marrow mononuclear cells from multiple myeloma (MM) patients than in healthy subjects. Serum BCMA levels were measured in samples from MM patients (n = 209), monoclonal gammopathy of undetermined significance (MGUS) individuals (n = 23) and age-matched controls (n = 40). BCMA was detected in the serum of untreated MM patients (n = 50) and levels were higher than in MGUS patients (P = 0.0157) and healthy subjects (P < 0.0001). Serum BCMA levels were higher among patients with progressive disease (n = 80) compared to those with responsive disease (n = 79; P = 0.0038). Among all MM patients, overall survival was shorter among patients whose serum BCMA levels were above the median (P = 0.001). We also demonstrated that sera from mice with human MM xenografts contained human BCMA, and levels correlated with the change in tumour volume in response to melphalan or cyclophosphamide with bortezomib. These results suggest that serum BCMA levels may be a new biomarker for monitoring disease status and overall survival of MM patients.